Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MRK

Merck & Co Inc

Dec 24 • 04:00PM ET

99.45

Dollar change +0.08
Percentage change 0.08	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE JNJ ABBV BMY AMGN LLY REGN GILD VRTX BHC

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM IWF VHT

Scroll to Statements

Index	DJIA, S&P 500	P/E	20.83	EPS (ttm)	4.77	Insider Own	0.09%	Shs Outstand	2.53B	Perf Week	-0.47%
Market Cap	251.57B	Forward P/E	10.53	EPS next Y	9.44	Insider Trans	0.00%	Shs Float	2.53B	Perf Month	0.41%
Income	12.15B	PEG	0.74	EPS next Q	1.81	Inst Own	78.93%	Short Float	1.27%	Perf Quarter	-13.20%
Sales	62.89B	P/S	4.00	EPS this Y	412.48%	Inst Trans	-0.04%	Short Ratio	2.82	Perf Half Y	-24.27%
Book/sh	17.58	P/B	5.66	EPS next Y	22.00%	ROA	10.83%	Short Interest	32.03M	Perf Year	-7.53%
Cash/sh	5.79	P/C	17.19	EPS next 5Y	28.00%	ROE	28.33%	52W Range	94.48 - 134.63	Perf YTD	-8.65%
Dividend Est.	3.10 (3.12%)	P/FCF	16.95	EPS past 5Y	-42.70%	ROI	15.28%	52W High	-26.13%	Beta	0.41
Dividend TTM	3.12 (3.14%)	Quick Ratio	1.15	Sales past 5Y	7.72%	Gross Margin	73.03%	52W Low	5.26%	ATR (14)	2.06
Dividend Ex-Date	Dec 16, 2024	Current Ratio	1.36	EPS Y/Y TTM	163.70%	Oper. Margin	23.00%	RSI (14)	45.89	Volatility	1.91% 1.99%
Employees	72000	Debt/Eq	0.86	Sales Y/Y TTM	8.17%	Profit Margin	19.32%	Recom	1.69	Target Price	128.00
Option/Short	Yes / Yes	LT Debt/Eq	0.79	EPS Q/Q	-33.34%	Payout	2065.60%	Rel Volume	0.33	Prev Close	99.37
Sales Surprise	1.11%	EPS Surprise	5.80%	Sales Q/Q	4.42%	Earnings	Oct 31 BMO	Avg Volume	11.36M	Price	99.45
SMA20	-1.52%	SMA50	-2.46%	SMA200	-15.49%	Trades		Volume	3,713,479	Change	0.08%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115
Mar-06-23	Initiated	Jefferies	Buy	$125
Feb-22-23	Upgrade	Wolfe Research	Peer Perform → Outperform	$127
Jan-04-23	Upgrade	BofA Securities	Neutral → Buy	$110 → $130
Nov-18-22	Initiated	Credit Suisse	Outperform	$120
Oct-10-22	Upgrade	Guggenheim	Neutral → Buy

Show Previous Ratings

Dec-24-24 05:45PM	Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
12:20PM	3 biggest catalysts expected for healthcare in 2025 (Yahoo Finance Video)
Dec-21-24 07:30AM	Personalis price target raised to $8 from $7 at BTIG (TipRanks)
06:50AM	Merck closes exclusive global license agreement for LM-299 from LaNova Medicines (TipRanks)
Dec-20-24 09:44AM	BMO cuts rating on Merck and Biogen, on lack of near term catalyst (Investing.com)
09:00AM	Loading…
09:00AM	Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know (Zacks)
07:12AM	Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? (Insider Monkey)
06:45AM	Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody (Business Wire)
Dec-19-24 01:39PM	Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials (Benzinga)
10:00AM	A venture firm breathes new life into an old NGM drug (BioPharma Dive)
07:32AM	MSD makes obesity play in up to $2bn deal for Hansohs GLP-1RA asset (Pharmaceutical Technology)
06:45AM	Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection (Business Wire)
06:12AM	Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In? (Insider Monkey)
03:00AM	Mercks RSV antibody could soon paddle into the rough waters of a crowded market (Pharma Voice)
Dec-18-24 04:06PM	Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal With Someone Else (Investor's Business Daily)
01:12PM	Loading…
01:12PM	What's Going On With Viking Therapeutics Stock On Wednesday? (Benzinga)
11:52AM	Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute (Yahoo Finance Video)
09:14AM	Strong Fundamentals And Weight Loss Entry Make Merck (MRK) A Buy (Insider Monkey)
09:07AM	Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche (Investor's Business Daily)
06:59AM	Merck moves into obesity with deal for Hansohs GLP-1 pill (BioPharma Dive)
06:45AM	Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist (Business Wire)
Dec-17-24 02:15PM	Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis (Benzinga)
07:18AM	Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
07:11AM	Merck targets 2025 RSV season with antibody now under FDA review (BioPharma Dive)
06:45AM	Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season (Business Wire)
03:00AM	Maternal mortality trends remain dire and researchers face an uphill battle to solve them (Pharma Voice)
Dec-16-24 04:30PM	Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab (Business Wire)
06:45AM	Merck's KEYTRUDA (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC (Business Wire)
06:20AM	Merck calls quits on two immunotherapies for cancer (BioPharma Dive)
Dec-13-24 07:05AM	Merck Receives Positive EU CHMP Opinion for WELIREG (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma (Business Wire)
03:00PM	Loading…
Dec-12-24 03:00PM	How HP, Merck And Virtus Investment Partners Can Put Cash In Your Pocket (Benzinga)
Dec-11-24 02:10PM	AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients (Benzinga)
10:22AM	LYNPARZA (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial (Business Wire)
Dec-10-24 11:47PM	Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now? (Insider Monkey)
07:00AM	How Much Would It Take To Earn $100 A Month From Merck Stock (Benzinga)
Dec-09-24 10:50AM	Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer (Benzinga)
07:15AM	ASH24: Darzalex in smoldering myeloma, Mercks ADC data and Novos sickle cell drug (BioPharma Dive)
06:45AM	Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer (Business Wire)
01:17AM	Why Merck & Co. (MRK) Is the Best Beginner Stock to Invest in Now? (Insider Monkey)
Dec-08-24 03:00PM	Mercks Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma (Business Wire)
Dec-06-24 01:29PM	Why Merck & Co. (MRK) Is Among the Best Affordable Stocks to Buy Right Now (Insider Monkey)
Dec-05-24 01:45PM	Merck Earns Top Spot on Newsweek's List of America's Most Responsible Companies 2025 (ACCESSWIRE)
09:00AM	Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:48AM	Heres What is Powering Merck & Co.s (MRK) Earnings Growth (Insider Monkey)
06:45AM	Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults (Business Wire)
Dec-04-24 09:25AM	HSBC upgrades Merck stock to Buy on 2025 opportunities (Investing.com)
06:50AM	Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan (TipRanks)
Dec-03-24 03:10PM	Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment (GuruFocus.com)
06:45AM	FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations (Business Wire)
Dec-02-24 07:46AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
07:13AM	Why Is Merck & Co., Inc. (MRK) Among the Stocks Ray Dalios Bridgewater Is Crazy About? (Insider Monkey)
Nov-26-24 09:11AM	Merck & Co. (MRK) Fell As It Faced Some Demand Headwinds In China (Insider Monkey)
06:50AM	Merck reports positive results from Phase 3 ZENITH trial evaluating Winrevair (TipRanks)
06:45AM	Merck to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-25-24 12:02PM	Why Is Merck Stock Trading Higher On Monday? (Benzinga)
06:57AM	New data could help Merck expand use of cardiovascular drug (BioPharma Dive)
06:45AM	Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR (sotatercept-csrk) Met Primary Endpoint at Interim Analysis (Business Wire)
04:22AM	Merck & Co., Inc. (MRK): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-23-24 10:18AM	Hedge Funds Bet Big On Merck & Co. (MRK): Top Healthcare Stock to Watch (Insider Monkey)
10:18AM	Hedge Funds Bet Big On Merck and#038; Co. (MRK): Top Healthcare Stock to Watch (Insider Monkey)
06:30AM	U.S. FDA found asthma drug Singular, montelukast impacts the brain, Reuters says (TipRanks)
Nov-22-24 04:17PM	Merck Recommends Rejection of TRC Capitals Mini-Tender Offer (Business Wire)
09:00AM	Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know (Zacks)
07:15AM	Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
06:45AM	Mercks WELIREG (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors (Business Wire)
06:30AM	Surendralal Karsanbhai Elected to Merck Board of Directors (Business Wire)
06:19AM	Goldman Sachs: Merck & Co., Inc. (MRK) Is A Top Growth Investor Stock (Insider Monkey)
06:03AM	Exclusive-US FDA finds widely used asthma drug impacts the brain (Reuters)
Nov-21-24 06:45AM	Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities (Business Wire)
02:12AM	Keytruda represents almost half of Mercks sales, and a new formulation could fend off rivals (Pharma Voice)
Nov-20-24 03:10PM	Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care (ACCESSWIRE)
02:14PM	Merck & Co., Inc. (MRK)s Blockbuster Drugs: A Key Player in Ken Griffins Portfolio (Insider Monkey)
Nov-19-24 01:17PM	Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients (Benzinga)
12:22PM	Merck Announces First-Quarter 2025 Dividend (Business Wire)
06:47AM	Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says (BioPharma Dive)
06:45AM	Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints (Business Wire)
Nov-18-24 06:00PM	Jim Cramer Says Merck & Co., Inc. (MRK) Is Just Way Too Hated' (Insider Monkey)
09:49AM	Is Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
02:53AM	Why Merck rolled the dice on an unbelievable early-stage brain cancer drug (Pharma Voice)
12:44AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
Nov-15-24 04:18PM	How analysts are reacting to RFK Jr. as Trump's HHS pick (Yahoo Finance Video)
09:43AM	Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of. (Yahoo Finance)
07:15AM	Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) (Business Wire)
Nov-14-24 04:54PM	Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics (Investor's Business Daily)
07:15AM	Merck to Participate in the Jefferies London Healthcare Conference (Business Wire)
06:45AM	Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. (Business Wire)
05:39AM	Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy (BioPharma Dive)
Nov-13-24 06:56AM	Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial (TipRanks)
05:26AM	MSD and AstraZeneca report positive topline data from Koselugo trial for NF1 (Clinical Trials Arena)
Nov-12-24 06:45AM	KOSELUGO (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial (Business Wire)
03:00AM	Merck to Present New Data From GARDASIL9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024 (Business Wire)
Nov-09-24 10:41AM	Merck & Co., Inc. (MRK): Among the Best Low Volatility Stocks to Invest In Now (Insider Monkey)
Nov-08-24 02:47PM	Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement (PR Newswire)
11:23AM	Why WEC Energy, Merck And Regions Financial Are Winners For Passive Income (Benzinga)
09:36AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
09:00AM	Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock (Zacks)
Nov-07-24 10:36AM	Merck & Co., Inc. (MRK) Makes It On UBS List Of Stocks For The AI, Growth & Low Rates Era (Insider Monkey)
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-06-24 06:45AM	Merck to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-04-24 06:41PM	Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy Right Now? (Insider Monkey)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guindo Chirfi	Chief Marketing Officer	Aug 05 '24	Option Exercise	115.20	36,901	4,250,995	57,782	Aug 06 12:20 PM
Smart Dalton	SVP Fin. - Global Controller	May 03 '24	Option Exercise	128.26	2,046	262,420	4,708	May 06 04:10 PM
Smart Dalton	SVP Fin. - Global Controller	May 04 '24	Option Exercise	127.51	612	78,036	4,730	May 06 04:10 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 04 '24	Option Exercise	127.51	27,126	3,458,836	163,720	May 06 04:08 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 04 '24	Option Exercise	127.51	887	113,101	24,058	May 06 04:06 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 04 '24	Option Exercise	127.51	912	116,289	24,271	May 06 04:01 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '24	Option Exercise	128.80	2,262	291,346	21,831	May 02 04:29 PM
Smart Dalton	SVP Fin. - Global Controller	May 02 '24	Option Exercise	128.80	381	49,073	3,048	May 02 04:23 PM
Merck & Co., Inc.	10% Owner	Mar 11 '24	Buy	23.00	21,397,205	492,135,715	1,000	Mar 11 03:27 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Option Exercise	58.08	38,291	2,223,941	89,199	Feb 15 04:03 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Sale	125.50	38,291	4,805,520	50,908	Feb 15 04:03 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Option Exercise	74.18	150,000	11,127,160	498,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Option Exercise	73.73	85,021	6,268,598	433,348	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Sale	125.85	150,000	18,877,424	348,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Sale	125.40	85,021	10,661,574	348,327	Feb 15 04:01 PM
Romanelli Joseph	President, Human Health Int?l	Feb 13 '24	Sale	124.89	1,000	124,888	19,569	Feb 14 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Option Exercise	62.07	14,702	912,553	60,944	Feb 12 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Sale	125.50	14,702	1,845,083	46,242	Feb 12 04:03 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 07 '24	Sale	127.57	1,451	185,108	19,812	Feb 08 04:04 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Option Exercise	78.80	20,937	1,649,906	42,286	Feb 05 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Sale	127.17	18,959	2,411,111	23,327	Feb 05 04:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Option Exercise	73.65	32,994	2,430,159	74,313	Feb 02 04:07 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Sale	126.65	50,694	6,420,349	23,619	Feb 02 04:07 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Option Exercise	87.10	19,417	1,691,221	78,557	Feb 02 04:05 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Sale	126.97	49,499	6,284,779	29,058	Feb 02 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience